Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immuneering (IMRX) Research & Development (2020 - 2026)

Immuneering's Research & Development history spans 7 years, with the latest figure at $10.6 million for Q1 2026.

  • On a quarterly basis, Research & Development fell 7.2% to $10.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $41.2 million, a 14.54% decrease, with the full-year FY2025 number at $42.0 million, down 12.33% from a year prior.
  • Research & Development came in at $10.6 million for Q1 2026, up from $9.3 million in the prior quarter.
  • The five-year high for Research & Development was $14.9 million in Q4 2024, with the low at $8.0 million in Q2 2022.
  • Historically, Research & Development has averaged $10.5 million across 5 years, with a median of $10.5 million in 2025.
  • Biggest five-year swings in Research & Development: skyrocketed 68.03% in 2022 and later plummeted 37.71% in 2025.
  • Year by year, Research & Development stood at $9.9 million in 2022, then rose by 20.65% to $11.9 million in 2023, then grew by 24.74% to $14.9 million in 2024, then crashed by 37.71% to $9.3 million in 2025, then grew by 15.03% to $10.6 million in 2026.
  • Business Quant data shows Research & Development for IMRX at $10.6 million in Q1 2026, $9.3 million in Q4 2025, and $10.9 million in Q3 2025.